

## **Aerobic bacteriology of Chronic Suppurative Otitis Media (CSOM) in a tertiary care hospital: A retrospective study**

R. K. Sanjana<sup>1</sup>, Y. I. Singh<sup>2</sup>, N.S.Reddy<sup>3</sup>

<sup>1</sup>Assistant Professor, <sup>2</sup>Prof & Head, Dept of Microbiology, <sup>3</sup>Prof & Head, Dept. of Ear Nose and Throat (ENT), College of Medical Sciences- Teaching Hospital, Bharatpur, Chitwan District, Nepal.

### **Abstract**

The present study was carried out to determine the aerobic microorganisms involved and their antibiotic sensitivity pattern in patients with Chronic Suppurative Otitis Media (CSOM) and to provide a guideline for empirical antibiotic therapy.

Between March 2009 to February 2011, the ear discharge samples submitted at the microbiology laboratory were processed aerobically and all the isolates were included in this study. All organisms were identified morphologically and biochemically by standard laboratory procedures and antibiotic susceptibility pattern was determined by modified Kirby Bauer disc diffusion method as per National Committee for Clinical Laboratory Standard recommendations.

Out of a total of 214 samples, microbiological culture was yielded from 202 (94.3%) specimens. Single organism were isolated from 168 (78.5%) of the culture positive specimens, while the remaining 34 (15.9%) had two or more organisms isolated. *Pseudomonas aeruginosa* 59 (35.1%) was the most common isolate, followed by *Staphylococcus aureus* 42 (25.0%) including 5 (3%) of the Methicillin Resistant *Staphylococcus Aureus* (MRSA). Antibiotic sensitivities of *Pseudomonas aeruginosa* showed that 93.2% isolates were sensitive to tobramycin, whereas, 91.5% isolates were sensitive to ceftazidime and 77.9% to amikacin. Only 50.8% of the isolates of *Pseudomonas aeruginosa* were sensitive to ciprofloxacin and 25.4% to gentamicin. For *Staphylococcus aureus* (other than MRSA) 95.2% were sensitive to cloxacillin, 83.3% to gentamicin and 78.5% to erythromycin. Only 07.1% were sensitive to ampicillin and 26.1% to ciprofloxacin.

*Pseudomonas aeruginosa* was the most common isolate followed by *Staphylococcus aureus*. More than 90% of *Pseudomonas* and 90% of *Staph aureus* were sensitive to tobramycin and cloxacillin respectively. Therefore, these two drugs may be included in the formulary to cover the most common aerobic isolates involved in CSOM.

**Key words:** Chronic suppurative otitis media, *Pseudomonas aeruginosa*, antibiotic sensitivity.

---

Correspondence: R.K. Sanjana

E-mail: rajkumari\_sanjana@yahoo.co.in

## Introduction

Chronic suppurative otitis media (CSOM) is a commonly encountered infection of the middle ear. The most acceptable definition is that CSOM is an infection of the middle ear that lasts more than 3 months and is accompanied by tympanic membrane perforation.<sup>1</sup> It is one of the most common diseases of all age groups, especially of childhood. The disease is prevalent in developing countries and is a disease of the poverty.<sup>2</sup>

Chronic suppurative otitis media has profound impact on society in terms of resources utilized in treatment and direct impact that chronic infection has on hearing on patient.<sup>3</sup> It causes conductive and sensorineural hearing loss and adverse effect on childhood development.<sup>4</sup> The first line of treatment of CSOM is topical therapy. Concerns about ototoxicity leads to decline in use of aminoglycosides containing ear drops. Quinolone containing ear drops exhibit excellent antipseudomonal and broad spectrum antimicrobial activity and non-ototoxicity.<sup>5,6</sup>

In chronic suppurative otitis media the most frequently isolated bacteria are *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Proteus species* and *Klebsiella species*.<sup>2</sup> Knowledge of the local pattern of infection is essential to enable efficacious treatment of this disorder.

This study is aimed at finding the local pattern of aerobic microbes involved and their antimicrobial sensitivity pattern in cases of chronic suppurative otitis media to provide a guideline for empirical antibiotic therapy.

## Materials and methods

This study was based on retrospective data of samples sent from the department of ear, nose and throat (ENT) of College of Medical Sciences-Teaching Hospital, Bharatpur. A total of 214 purulent discharge samples from the clinically diagnosed cases of CSOM during March 2009 to February 2011 that were sent for culture and sensitivity to the Microbiology lab were included in this study. Sterile cotton swab sticks were used to collect the samples.

The pus swabs were cultured on Blood and MacConkeys agar and incubated aerobically at 37°C for an overnight. All organisms isolated were identified according to standard microbiological methods.<sup>7</sup> Antimicrobial susceptibility test was performed using Kirby- Bauer disc diffusion method and updated by Clinical and Laboratory Standards Institute guidelines.<sup>8</sup> The standard antimicrobial discs (HI Media Laboratoriers, Pvt. Ltd, Mumbai) used for *Staph aureus* were oxacillin (1µg), cotrimoxazole (25µg), penicillin (10U), cloxacillin (10 µg), gentamicin (10µg), chloramphenicol (30µg), ciprofloxacin (5µg), and vancomycin (10µg). American Type Culture Collection (ATCC) 43300 was used as the control. The standard antimicrobial discs used for (HI Media) *Pseudomonas aeruginosa* were gentamicin (10µg), chloramphenicol (30µg), ciprofloxacin (5µg), ceftazidime (30µg), piperacillin (100µg), carbenecillin (100µg), and tobramycin (10µg). ATCC 27853 was used as control organism.

**Results**

From 214 samples studied, microbiological culture was yielded from 192 samples (89.7%). One hundred and sixty-eight samples (78.5%) had a single organism isolated from the middle ear discharge, while the remaining 34 (15.9%) had two or more organisms isolated. There were 12 (05.6%) samples who had a sterile culture with no organism isolated. (Table-I)

**Table I**

<b>Organism cultured from ear discharge</b>		
<b>Type of organism</b>	<b>Total isolates</b>	<b>Percentage</b>
Pure growth	168	78.5 %
Mixed growth	34	15.9 %
No growth	12	05.6 %
<b>Total</b>	<b>214</b>	<b>100%</b>

The most common causal organism isolated were *Pseudomonas aeruginosa* 59 (35.1%) and *Staphylococcus aureus* 42 (25.0%), of which 05 (03.0%) were Methicillin Resistant *Staphylococcus aureus* (MRSA) followed by Coagulase negative staphylococcus 17 (10.1%). Fungi accounted for 15 (08.5%) of the total organisms isolated from the pure culture. (Table-II)

**Table II**

<b>Pure growth in culture of CSOM (n=168)</b>		
<b>Type of organism</b>	<b>Total isolates</b>	<b>Percentage</b>
<i>Pseudomonas aeruginosa</i>	<b>59</b>	<b>35.1</b>
<i>Staphylococci aureus</i> (MSSA)	37	22.0
MRSA	05	03.0
CONS	17	10.1
<i>Klebsiella species</i>	13	07.7

<i>Escherichia coli</i>	10	07.7
<i>Proteus spp</i>	05	03.0
<i>Enterobacter spp</i>	05	03.0
<i>Citrobacter spp</i>	02	01.1
<i>Candida spp</i>	06	03.5
<i>Aspergillus spp</i>	09	05.3
<b>Total</b>	<b>168</b>	

*Pseudomonas species* was isolated in 11 (32.3%) of the total samples that yielded multi- organisms, *Staph aureus* in 07 (19.7%), *Klebsiella species* in 04 (11.6%), *Proteus species* 04 (11.6%), followed by *Escherichia coli* 03 (08.8%). (Table-III)

**Table III**


<b>Mixed growth in culture of CSOM (n=34)</b>		
<b>Type of organism</b>	<b>No of isolates</b>	<b>Percentage</b>
<i>Pseudomonas spp</i>	11	32.3
<i>Staphylococci aureus</i> (MSSA)	05	14.7
MRSA	02	05.8
<i>Klebsiella species</i>	04	11.7
<i>Proteus spp</i>	04	11.7
<i>Escherichia coli</i>	03	08.8
<i>Candida spp</i>	03	08.8
<i>Aspergillus spp</i>	02	05.8
<b>Total</b>	<b>34</b>	

The antibiotic sensitivity pattern of the two most common isolates, *Pseudomonas aeruginosa* and *Staphylococcus aureus* (other than MRSA) is depicted in (Fig 1 & 2) respectively. Among *Pseudomonas aeruginosa*, tobramycin has the highest susceptibility rate (93.2%), followed by ceftazidime (91.5%) and amikacin (64.4%).


*Staphylococcus aureus* is most susceptible to Cloxacillin (95.2%), followed by erythromycin (83.3%) and gentamicin (78.5%).

All the seven isolates of MRSA were multidrug resistant; however, none of these were resistant to vancomycin.

**Antibiogram of Pseudomonas aeruginosa:**



**Antibiogram of Staphylococcus aureus:**



## Discussion

CSOM is a condition of the middle ear that is characterised by persistent or recurrent discharge through a chronic perforation of the tympanic membrane. Due to the perforated tympanic membrane, bacteria can gain entry into the middle ear via the external ear canal. Infection of the middle ear mucosa subsequently results in ear discharge. It is a persistent disease with great risk of irreversible complications. Such complications range from persistent otorrhoea, mastoiditis, labyrinthitis, and facial nerve paralysis to more serious intracranial abscesses or thromboses.<sup>9</sup> Though the incidence of such complications is low; they need to be borne in mind when faced by a patient with active CSOM. Early bacteriological diagnosis of all cases will assure accurate and appropriate effective therapy. Selection of antibiotic is influenced by its efficacy, resistance of bacteria, safety, risk of toxicity and costs.<sup>9</sup>

Knowledge of the local microorganisms, pattern and their antibiotic sensitivity is then essential to formulate a protocol for empirical antibiotic therapy.

Different studies on the microbiology of CSOM have revealed that the most frequently isolated bacteria were *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Coagulase negative Staphylococcus*, *Proteus species*, *Klebsiella species* and fungi.<sup>5, 9, 10, 11</sup>

Our study has revealed that active infection of CSOM patients visiting the hospital is mainly due to *Pseudomonas aeruginosa* (35.1%) and

*Staphylococcus aureus* (25.0%) This finding is in tandem with the pattern of CSOM infection of the other studies mentioned above. There was also significantly high number of fungal isolates (8.5%) in our study.

Review of literature about the studies done to find out bacterial flora in cases of CSOM in a state of India reveals that whereas *Pseudomonas aeruginosa* remained as the premier isolate in two studies, the isolation rate of *Staphylococcus aureus* in one of the study was quite low whereas other gram negative rods (i, e) *Klebsiella pneumonia*, *Proteus mirabilis* and *Escherichia coli* was relatively high.<sup>12,13</sup> The third most commonly isolated organism, in our study, *coagulase negative Staphylococcus* (CONS) may represent skin flora contamination, and not be a true pathogen. However, one should not neglect any organism that is isolated from the infection.

Antimicrobial sensitivities of *Pseudomonas aeruginosa* in our study revealed that 93.2% isolates were sensitive to tobramycin while 91.5% of isolates were sensitive to ceftazidime and 77.9% to carbenecillin. On the other hand, 64.4% of isolates were sensitive to amikacin and 61.0% to ceftriaxone. 50.8% of the isolates were susceptible to ciprofloxacin.

A study carried out in Turkey<sup>14</sup> in 1996 revealed only 6% of *pseudomonas aeruginosa* isolates to be resistant to ciprofloxacin; whereas, in South Korea in a study carried out in 2004, ciprofloxacin resistance was noted in 100% of isolates.<sup>15</sup> In studies carried out in Pakistan revealed that more than 90%

isolates of *Pseudomonas aeruginosa* were sensitive to ciprofloxacin.<sup>16, 17, 18, 19</sup>

In contrast, our study has shown only 50.8% of the isolates to be sensitive to ciprofloxacin. The declining sensitivity trend may be due to number of factors including injudicious use, inappropriate dosage, easy accessibility and developing enzymatic resistance of organisms especially *Pseudomonas aeruginosa*, *Staphylococcus aureus* and some *Enterobacteriaceae* against quinolones.<sup>20, 16</sup>

Similar activity is noted as far as in vitro activity of aminoglycosides against *Pseudomonas aeruginosa* is concerned. Studies done in Singapore and India<sup>9, 13</sup> had shown significantly higher percentage of *Pseudomonas aeruginosa* isolates sensitive to gentamicin compared to our studies where only 20.3% of the isolates were susceptible to this antibiotic. However, our finding is comparable to the study done by Ahmed Bel et, al.<sup>17</sup>

As far as topical preparation is concerned for the treatment of CSOM, the otolaryngologist has either quinolones or aminoglycosides in their armory. Studies done by AHC Loy et, al;<sup>21</sup> in 2002 published that gentamicin was most effective among topical ear drops. However, the authors discussed the controversies over the question of ototoxicity with the topical usage of aminoglycosides, such as gentamicin. In another study by Kardar AA et, al;<sup>22</sup> had shown quinolones better results compared to topical aminoglycosides. Similar findings were also shown by other researchers,<sup>23, 24</sup> indicating the effectiveness of topical quinolones particularly against *Pseudomonas aeruginosa* and *Staph aureus*.

Hence, they would provide a viable alternative for the treatment of patients with active CSOM. At the same time, one should be concern about the fact that the widespread use of quinolones such as ofloxacin and ciprofloxacin could lead to emergence of resistance.

The antibiotic sensitivity pattern of *Staphylococcus aureus* (other than MRSA) in our study revealed that 95.2% of the isolates were sensitive to cloxacillin, 83.3% to gentamicin 78.5% to erythromycin and only 26.1% to ciprofloxacin. Least susceptibility was seen in ampicillin i.e. 07.1%. The susceptibility pattern of *Staph aureus* found in our study against most of the antibiotics is almost consistent with other studies.<sup>16, 17 and 18</sup> However, our findings revealed lower sensitivity rate to ciprofloxacin (26.1%) as compared to the study done by Ahmed B et al.<sup>17</sup>

## Conclusion

*Pseudomonas aeruginosa* was the most common isolate followed by *Staphylococcus aureus*. Majority of *Pseudomonas aeruginosa* isolate (93.2%) were sensitive to tobramycin and only 50.8% to ciprofloxacin. For *Staphylococcus aureus* (other than MRSA), 95.2% were sensitive to cloxacillin, 83.3% to gentamicin and only 26.1% of the isolates were sensitive to ciprofloxacin. Hence, our study revealed ciprofloxacin to be of less effective in the treatment of active CSOM. This report showed that in our hospital, tobramycin and cloxacillin may be included in the formulary to cover the most common isolates involved in CSOM. Nevertheless, more research needs to be done on the role of topical drugs in chronic suppurative otitis media.



## References

1. M. Goycoolea, L. Ruah. Definitions and Terminology. *Otol Clin of North Am* 1991; **24**:757-61.
2. S. Couzos, T. Lea, R. Mullar et al. Effectiveness of ototopical antibiotics for CSOM in Aboriginal children, a community based multicenter double blind randomized controlled trial. *Med J Aust* 2003; **179**(4): 185-90.
3. E. Alan, Dugdale. Management chronic suppurative otitis media. *Med J Aus* 2004; **180**(2): 91-3.
4. Y. El Sayed. Bone conduction impairment in uncomplicated CSOM. *Am J Otol.* 1998; **19**(1): 149-53.
5. N. Micro. Controlled multicenter study on CSOM treated with topical application of ciprofloxacin 0.2% solution. *Otolaryngol Head Neck Surg* 2000; **123**: 617-23.
6. R. Indudharan, J.A. Haq, S. Aigar. Antibiotics in CSOM. A bacteriologic study. *Ann Otol. Rhino Laryngol* 1999; **108** (5): 440-5.
7. J.P. Duiguilid, J.G. Collee, A.G. Fraser. Laboratory strategy in the diagnosis of infective syndromes. In J.G. Collee, B.P. Marmion, A.G. Fraser, Simmons A. Mackie and Macartney practical medical microbiology. 14<sup>th</sup> ed. London: 1996.
8. Clinical and Laboratory Institute. Performance standards for antimicrobial susceptibility testing; 16<sup>th</sup> information supplement (M100- S16). Clinical and Laboratory Standards Institute, Wayne, Pa: 2006.
9. A.H.C. Loy, A.L. Tan, P.K.S. Lu. Microbiology of Chronic Suppurative Otitis Media in Singapore. *Singapore Med J* 2000; **43** (6): 296- 9.
10. O. Nekwa, Z.A. Shareef, A. Benayama. Anaerobes and fungi in chronic suppurative otitis media. *Ann otorhino Laryngol* 1997; **106**(5): 649-52.
11. V. Khanna, J. Chander, N.M. Nagarkar et al. Clinicomicrobiologic evaluation of active tubotympanic type chronic suppurative otitis media. *J Otol.* 2000; **29**(3): 148-53.
12. S.L. Hiremath, R.C. Kanta, M. Yeshwanth rao et al. Aerobic bacterial isolates of CSOM and their antibiotic sensitivity pattern. *Ind Pract J* 2001; **54**(7): 486-9.
13. V.K. Poorey, A. Lyer. Study of bacterial flora in CSOM and its clinical significance. *Ind J Otol. and Head and Neck Surg* 2002; **54**(2): 91-8.
14. C.H. Jang, S.Y. Park. Emergence of ciprofloxacin resistant pseudomonas in chronic suppurative otitis media. *Cli Otol.* 2004; **29**(7): 321-3.
15. A. Altuntas, A. Aslam, A. Eren et al. Susceptibility of microorganisms isolated from chronic suppurative otitis media to ciprofloxacin . *Eur Arch Otol-rhino-laryngol* 1996; **253**:364-6.
16. M.A. Aslam, Z. Ahmed, R. Azim. Microbiology and drug sensitivity patterns of chronic suppurative otitis media. *J Col Physicians Surg Pak* 2004; **8**(14): 459-61.
17. B. Ahmed, S. Hydri, A.A.K. Afridi et al. Microbiology of ear discharge in Quetta. *J Coll Physicians Surg Pak* 2005; **15**(9): 583-4.
18. Y. Taj, F. Essa, S.U. Kazmi. Pathological analysis of 596 cases of chronic suppurative otitis media in Karachi. *J Coll Physicians Surg Pak.* 2000; **10**(4): 33-5.
19. A. Ahmed, J. Usman, R. Hashim. Isolates from chronic suppurative otitis media and their antibiotic sensitivity. *Pak Armed Forces Med J* 1999; **49**(12): 82-5.
20. E. Vartiainen, J. Vartiainen. Effect of aerobic bacteriology on the clinical presentation and treatment results of chronic suppurative media. *J Laryngol Otol* 1996; **110**: 315-8.
21. A.H.C. Loy, A. Tan, P.K.S. Lu. Microbiology of chronic suppurative otitis media in Singapore. *Singapore Med J* 2002; **43**(6): 296-9.

22. A.A. Kardar, M. Usman, S. Tirmizi. Topical quinolone versus topical aminoglycosides in the medical management of chronic suppurative otitis media; A comparative trial. *J Surg Pak* 2003; **8** (4): 6-9.
23. A.P. Yuen, P.Y. Chau, Wei. Bacteriology of chronic suppurative otitis media; ofloxacin susceptibility. *J Otol.* 1995; **24**(3): 206-8.
24. A.S. Agro, E.T. Garner, J.W. Wright et al. Clinical trial of ototopical ofloxacin for treatment of chronic suppurative otitis media. *Clin Ther* 1998; **20** (4): 744-59.